News | January 07, 2008

Sirolimus Stents May Reduce Restenosis in Diabetics with Coronary Disease

January 8, 2008 - Compared with paclitaxel-eluting stents (PES), sirolimus-eluting stents (SES) appear to decrease the risk of in-stent late luminal loss in diabetics with coronary artery disease, new research shows.

The optimal drug-eluting stents for diabetic patients has been unclear, lead author Fabrizio Tomai, M.D., from the European Hospital in Rome, and colleagues note in the January issue of Diabetes Care.

Comparing PES with SES has been difficult since there are so many individual variables that contribute to neointimal hyperplasia. In the present study, the researchers addressed this problem by comparing PES and SES directly in the same diabetic patient.

The study enrolled 60 patients with two or more significant de novo angiographic stenoses in different coronary segments. Overall, 60 lesions were successfully treated with PES and 60 with SES, the report shows. (Another 26 coronary lesions were treated with bare metal stents and were not included in the analysis.)

The main outcome measure was the occurrence of angiographic in-stent late luminal loss at eight-month follow-up. This was lower with the SES (0.26 mm) than with the PES (0.50 mm), a significant difference (p = 0.01).

On multivariate analysis, the type of drug-eluting stent was the only independent predictor of in-stent late luminal loss. Specifically, in-stent late luminal loss was 2.3-times more likely when a PES rather than a SES was used (p = 0.03).

Further research is needed to determine if the better angiographic results achieved with SES actually translate into long-term clinical benefits, the authors conclude.

Source: Reuters

For more information:

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Overlay Init